Evidence map›Paper›PMID 34729899›Full record

ReviewAngewandte Chemie (International ed. in English)2022

Development of Chiral Ligands for the Transition-Metal-Catalyzed Enantioselective Silylation and Borylation of C-H Bonds.

Bo Su, John F Hartwig

Abstract readReview
In one paragraph

Review in Angewandte Chemie (International ed. in English), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Chiral Spiro-Scaffolded C(spAngewandte Chemie (International ed. in English) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Desulfurative Borylation of Small Molecules, Peptides, and Proteins.Journal of the American Chemical Society · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bo SuState Key Laboratory of Medical Chemical Biology, College of Pharmacy, Nankai University, 38 Tongyan Road, Jinnan District, Tianjin, 300350, P. R. China.
John F HartwigDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0002-4157-468X

Funding

Discovery and Development of Organic Reactions Catalyzed by Transition Metals Valuable for Medicinal ChemistryR35GM130387 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI John F Hartwig · 2019 to 2026
$7.1M
NIGMS NIH HHS R35 GM130387NIGMS NIH HHS R35GM130387
6 · The paper itself

Abstract

Enantioselective reactions that install functional groups at the positions of unactivated C-H bonds can be envisioned to produce intermediates for the synthesis of the active ingredients in pharmaceuticals and agrochemicals directly from simple feedstocks. Among these C-H bond functionalization reactions, those that form carbon-silicon (C-Si) and carbon-boron (C-B) bonds have been pursued because the products of these reactions can be converted to those containing a wide range of functional groups and because compounds containing silicon and boron possess unique properties that can be valuable for medicinal and materials chemistry. Although the silylation and borylation of C-H bonds have undergone extensive development during the past two decades, enantioselective versions of these reactions were not known until a few years ago. In this Minireview, we present the rapid development of enantioselective silylation and borylation of C-H bonds, with an emphasis on the design and development of the types of chiral ligands needed to achieve these reactions and an intention to inspire an expansion of these types of transformations.

Indexed as

Boron CompoundsCatalysisLigandsMolecular StructureSilicon CompoundsStereoisomerismTransition ElementsBoron CompoundsLigandsSilicon CompoundsTransition ElementsborylationC−H bond functionalizationenantioselective C−H activationligand designsilylation

Identifiers

PMID34729899
PMCPMC9135162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.